Infliximab for Injection
Efficacy and safety are equivalent to the original drug (Johnson & Johnson/Merck & Co.
The first infliximab biosimilar marketed in China
Infliximab for Injection (Reminton), a recombinant anti-TNF-alpha chimeric monoclonal antibody, was approved for marketing by the National Medical Products Administration (NMPA) on July 14, 2021. It is the first infliximab biosimilar marketed in China. Taking advantage of CHO cell expression system, Remin_x005f ton has been proved with good efficacy, better safety, and lower immunogenicity in clinical studies.
Indications:
Crohn's disease in adults and children over 6 years of age, stulizing Crohn's disease,
ulcerative colitis in adults, ankylosing spondylitis, rheumatoid arthritis, and psoriasis.
Recommended reading
Related products
-
Bevacizumab Injection
Contact UsBevacizumab, an anti-vascular endothelial growth factor monoclonal antibody (anti-VEGF mAb)
-
-
Black Currant Juice Powder
Contact UsLatin Name: Ribes nigrum L.
Synonyms:
Part of Used: Fruit
Specifications: Freeze-dried, 80mesh; Freeze-dried, 80mesh
Appearance:
Application: Food Supplements,Nutritional Supplement, Functional Food, Beverages/Solid Beverage -
1408Wh Power Station with jump starter
Contact UsUnleash power with our 1408Wh Power Station & Jump Starter.
Reviews
There are no reviews yet.